Description
A selective PAR4 antagonist (IC50 = 0.56 nM); selective for PAR4 over PAR1, PAR2, and a panel of purified proteases; inhibits platelet aggregation in vitro in human platelet-rich plasma (IC50 = 7.3 nM); decreases platelet aggregation ex vivo at a dose of 0.2-1 mg/kg; prevents vascular occlusion and reduces thrombus formation by 82% in cynomolgus monkeys
Formal name: 2-methoxy-6-[6-methoxy-4-[[5-methyl-2-(4-morpholinyl)-4-thiazolyl]methoxy]-2-benzofuranyl]-imidazo[2,1-b]-1,3,4-thiadiazole
Synonyms:
Molecular weight: 513.6
CAS: 1478712-37-6
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Blood|Coagulation & Hemostasis||Research Area|Cardiovascular System|Blood|Thrombosis